Clinical Trial Update: Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating pegvisomant, a growth hormone receptor antagonist, for severe insulin resistance due to insulin receptor mutation and partial lipo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Receptor Mutation
• Partial Lipodystrophy

Drugs mentioned

• Pegvisomant (pegvisomant)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Insulin Receptor Mutation, Partial Lipodystrophy | Phase 2 | Status: RECRUITING